Equities

Mercator Medical SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Mercator Medical SA

Actions
Health CareMedical Equipment and Services
  • Price (PLN)40.95
  • Today's Change0.00 / 0.00%
  • Shares traded2.22k
  • 1 Year change-16.77%
  • Beta0.0548
Data delayed at least 15 minutes, as of Feb 10 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Mercator Medical SA is a Poland-based company engaged in medical supplies industry. The Company manufactures medical gloves and distributes disposable medical materials. It produces medical, latex, synthetic, surgical, diagnostic sterile, examination and protective and household gloves. Its dressing products line includes gauze dressing products, non-woven fabric dressing, medical adhesive tapes, surgical dressing, among others. In addition, the Company provides drapes such as bed sheets, sets, as well as apparel, including caps, masks, gowns, among others. It operates through subsidiaries: Mercator Medical Kft, Mercator Medical srl, Merkator Medikal TOB, Mercator Medical (Thailand) Ltd and VIVOFT LLP.

  • Revenue in PLN (TTM)585.36m
  • Net income in PLN91.86m
  • Incorporated2001
  • Employees950.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Senzime AB (publ)35.81m-48.15m284.62m50.00--2.05--7.95-0.8672-0.86720.63942.220.2341.735.991,794,120.00-31.47-35.09-34.04-37.5241.868.75-134.46-400.654.30-7.700.0399--63.5554.1811.50--40.12--
Meditera Tibbi Mlzm Sny Tcrt AS202.67m-4.12m290.34m808.00--1.2937.861.43-0.4253-0.425320.9423.280.81082.844.853,257,490.00-1.876.25-2.237.4732.7042.44-2.316.902.17--0.01180.36-0.115155.2796.6241.97----
Agfa Gevaert NV4.66bn-299.64m322.12m4.74k--0.266--0.0691-0.468-0.47966.771.850.82522.394.78233,073.20-5.15-4.74-7.10-6.8629.7729.67-6.24-6.361.172.500.3798---1.04-10.44-71.70--3.44--
Medicalgorithmics SA26.80m-15.38m325.95m117.00--4.95--12.16-1.55-1.552.696.620.2520.39136.83229,034.20-14.46-3.04-15.68-3.6287.2885.62-57.38-8.771.25-15.740.2309---44.31-32.70-2,682.18---48.46--
Omda AS176.95m-11.28m327.14m260.00--25.7929.621.85-1.51-1.5123.591.630.679326.5921.701,772,075.00-4.33-5.14-5.39-6.6393.6991.09-6.37-10.320.64830.52810.9359--3.4515.80-163.95---15.57--
Gentian Diagnostics ASA64.28m15.94m333.28m63.0021.214.4317.265.182.732.7311.0713.100.81811.637.832,738,365.0020.29-2.9922.99-3.3655.0644.6624.80-5.844.16--0.0094--12.5225.96525.37--22.08--
Creo Medical Group PLC10.65m60.99m349.39m133.005.921.195.1932.810.02960.02720.00560.14770.0319-0.80340.330816,541.3518.25-29.2520.62-35.8945.4547.22572.73-176.824.75-69.500.0645--0.00212.28-17.30---18.58--
Nexstim Oyj42.48m-1.19m363.78m40.00--27.00129.878.56-0.042-0.0421.470.44260.85530.56134.66251,616.80-2.40-12.40-4.17-20.7694.3695.09-2.81-16.291.080.78350.6002--20.5521.1432.79--15.13--
Inspecs Group PLC933.39m-16.04m366.64m1.65k--0.85018.110.3928-0.0326-0.08061.900.87640.91382.317.71116,586.50-1.57-2.16-2.31-3.1351.8649.60-1.72-2.790.88471.730.3969---2.4832.80-362.19--4.97--
Mercator Medical SA585.36m91.86m379.56m950.004.140.4253.180.64849.899.8963.0596.360.58752.926.30616,168.409.2422.7810.0925.8716.1636.7515.7223.784.54--0.02582.0015.650.0796359.45--3.76--
Medinice SA19.00k37.36m384.00m11.008.154.1010.2120,210.665.085.080.002610.080.0003--0.03771,727.2763.4010.9565.1911.32-1,200.0049.36196,605.301,642.72----0.0024---16.442.77840.87--26.08--
Sedana Medical AB (publ)78.89m-16.23m396.16m117.00--1.09--5.02-0.4092-0.40921.999.140.20121.469.472,670,406.00-4.14-4.90-4.34-5.1670.4768.32-20.57-30.263.28-21.900.0045--16.1720.0682.09--26.45--
SDI Group PLC335.40m22.19m415.06m504.0019.071.679.461.240.0430.0430.64970.49230.7692--5.78137,484.105.127.085.818.87--63.936.658.601.195.750.33630.000.502721.99-5.848.9911.55--
ADDvise Group AB (publ)648.63m1.72m416.15m615.0019.910.94029.370.64160.08640.08643.441.830.51677.914.962,534,790.000.13993.410.1744.2839.9146.520.27086.060.75621.620.52510.438921.6836.71-13.0485.8552.63--
C Rad AB182.72m9.28m420.34m107.0046.233.0431.002.300.69220.692213.5810.53------4,623,273.00--8.44--11.7351.4545.005.088.282.983.310.02520.0010.4517.9658.88---9.15--
Paxman AB (publ)117.80m1.96m453.39m142.00177.022.6646.093.850.27570.275714.2618.380.84863.454.712,810,305.001.370.84261.601.2067.3468.751.610.79664.071.710.02450.0020.4124.30382.5570.92-3.73--
Data as of Feb 10 2026. Currency figures normalised to Mercator Medical SA's reporting currency: Polish New Zloty PLN

Institutional shareholders

1.57%Per cent of shares held by top holders
HolderShares% Held
Goldman Sachs Towarzystwo Funduszy Inwestycyjnych SAas of 30 Jun 2025119.10k1.29%
AgioFunds TFI SAas of 30 Dec 202523.42k0.25%
PKO TFI SAas of 30 Dec 20251.84k0.02%
Connor, Clark & Lunn Investment Management Ltd.as of 30 Jun 2025582.000.01%
American Century Investment Management, Inc.as of 30 Sep 2025146.000.00%
More ▼
Data from 30 Jun 2025 - 08 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.